{"id":"qiv-control","safety":{"commonSideEffects":[{"rate":"10-30%","effect":"Pain, redness, or swelling at the injection site"},{"rate":"10-20%","effect":"Fatigue"},{"rate":"10-20%","effect":"Headache"},{"rate":"10-20%","effect":"Muscle or joint pain"},{"rate":"5-10%","effect":"Fever"}]},"_chembl":{"chemblId":"CHEMBL1643772","moleculeType":"Small molecule","molecularWeight":"494.57"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"QIV control is a quadrivalent influenza vaccine that contains antigens from four different influenza viruses. This vaccine works by introducing small, harmless pieces of the influenza virus to the body, which triggers an immune response and helps the body produce antibodies to fight the virus.","oneSentence":"QIV control is a vaccine that stimulates the body's immune system to produce antibodies against the influenza virus.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:30:49.404Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prevention of influenza disease caused by four different strains of the influenza virus"}]},"trialDetails":[{"nctId":"NCT05945485","phase":"PHASE1","title":"A Study to Evaluate the Safety and Immunogenicity of Two Doses of DCVC H1 HA mRNA-LNP in Healthy Adults","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2023-10-16","conditions":"Influenza","enrollment":50},{"nctId":"NCT05227001","phase":"PHASE1","title":"A Study To Learn About The Study Vaccine (Called Self-Amplifying Ribonucleic Acid (RNA)) For The Prevention of Influenza","status":"COMPLETED","sponsor":"Pfizer","startDate":"2022-04-28","conditions":"Influenza, Human","enrollment":440},{"nctId":"NCT06431607","phase":"PHASE2","title":"A Study to Find the Dose and Assess the Immune Response and Safety of a Vaccine Against Influenza in Healthy Younger and Older Adults","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2024-05-23","conditions":"Influenza, Human","enrollment":845},{"nctId":"NCT05294588","phase":"PHASE2","title":"Efficacy of Immunization With 4C-MenB in Preventing Experimental Urethral Infection With Neisseria Gonorrhoeae","status":"COMPLETED","sponsor":"University of North Carolina, Chapel Hill","startDate":"2022-04-18","conditions":"Gonorrhea Male","enrollment":65},{"nctId":"NCT07211152","phase":"PHASE3","title":"Influenza Vaccine (Split Virion), Inactivated, Quadrivalent in Pregnant Women","status":"RECRUITING","sponsor":"Sinovac Biotech Co., Ltd","startDate":"2025-10-13","conditions":"Influenza","enrollment":150},{"nctId":"NCT06824519","phase":"PHASE1, PHASE2","title":"Clinical Trials of Quadrivalent Influenza Vaccine","status":"RECRUITING","sponsor":"Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.","startDate":"2025-05-08","conditions":"Influenza, Human","enrollment":620},{"nctId":"NCT05755620","phase":"PHASE1","title":"A Study to Evaluate the Safety and Immunogenicity of a Single Dose of H1ssF-3928 mRNA-LNP in Healthy Adults","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2023-04-05","conditions":"Influenza","enrollment":50},{"nctId":"NCT05526716","phase":"PHASE3","title":"A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V116 When Administered Concomitantly With Influenza Vaccine in Adults 50 Years of Age or Older (V116-005, STRIDE-5)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2022-09-23","conditions":"Pneumonia, Pneumococcal","enrollment":1080},{"nctId":"NCT05426174","phase":"PHASE1","title":"Study to Assess the Safety and Immunogenicity of Monovalent mRNA NA Vaccine in Adult Participants 18 Years of Age and Older","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2022-06-09","conditions":"Influenza Immunization, Healthy Volunteers","enrollment":233},{"nctId":"NCT06095947","phase":"","title":"Exploration on the Quadrivalent Influenza Vaccine Immunization Schedule for Children Aged 3-8 Years","status":"COMPLETED","sponsor":"Hualan Biological Bacterin Co. Ltd.","startDate":"2021-09-15","conditions":"GCP","enrollment":652},{"nctId":"NCT05144945","phase":"PHASE3","title":"Study Describing the Immunogenicity and Safety of Quadrivalent Recombinant Influenza Vaccine (RIV4) Versus a Licensed Quadrivalent-inactivated Influenza Vaccine (IIV4) (Fluarix® Quadrivalent) in Participants 18 Years of Age and Older in South Korea","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2021-12-07","conditions":"Influenza (Healthy Volunteers)","enrollment":301},{"nctId":"NCT06602024","phase":"PHASE3","title":"A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ≥50 Years of Age","status":"COMPLETED","sponsor":"ModernaTX, Inc.","startDate":"2024-09-16","conditions":"Seasonal Influenza","enrollment":40817},{"nctId":"NCT06049927","phase":"PHASE3","title":"A Phase III Clinical Trial of Quadrivalent Influenza Vaccine in Healthy Subjects Aged 6 to 35 Months","status":"COMPLETED","sponsor":"Sinovac Biotech Co., Ltd","startDate":"2023-09-16","conditions":"Seasonal Influenza","enrollment":3300},{"nctId":"NCT05801978","phase":"PHASE4","title":"Durability of Vaccine Responses","status":"RECRUITING","sponsor":"Emory University","startDate":"2023-04-11","conditions":"Vaccine Response","enrollment":66},{"nctId":"NCT06097273","phase":"PHASE3","title":"A Study of mRNA-1083 (SARS-CoV-2 and Influenza) Vaccine in Healthy Adult Participants, ≥50 Years of Age","status":"COMPLETED","sponsor":"ModernaTX, Inc.","startDate":"2023-10-19","conditions":"SARS-CoV-2, Influenza","enrollment":8061},{"nctId":"NCT06054269","phase":"PHASE3","title":"Clinical Trial to Evaluate the Immunogenicity of an Adjuvanted Influenza Vaccine Among HCP","status":"ACTIVE_NOT_RECRUITING","sponsor":"Centers for Disease Control and Prevention","startDate":"2022-11-04","conditions":"Influenza","enrollment":192},{"nctId":"NCT06015282","phase":"PHASE3","title":"The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older","status":"COMPLETED","sponsor":"Seqirus","startDate":"2023-11-03","conditions":"Influenza, Human","enrollment":7741},{"nctId":"NCT06134804","phase":"PHASE3","title":"A Study of 9-valent Extraintestinal Pathogenic Escherichia Coli Vaccine (ExPEC9V) and High-dose Quadrivalent Influenza Vaccine, With and Without Co-administration, in Adults Aged 65 Years or Older","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2023-10-24","conditions":"Invasive Extraintestinal Pathogenic Escherichia Coli Disease (IED) Prevention","enrollment":959},{"nctId":"NCT06342349","phase":"PHASE1","title":"A Clinical Trial of Quadrivalent Influenza Virus Split Vaccine (MDCK Cells) for Individuals Aged 6 Months and Above.","status":"COMPLETED","sponsor":"Shanghai Institute Of Biological Products","startDate":"2024-03-30","conditions":"Influenza","enrollment":300},{"nctId":"NCT06827873","phase":"NA","title":"Effect of Oral Supplements for Influenza Vaccine Response","status":"NOT_YET_RECRUITING","sponsor":"Tsinghua University","startDate":"2025-02","conditions":"Influenza Vaccine Response","enrollment":45},{"nctId":"NCT06800950","phase":"PHASE3","title":"Phase III Clinical Trial of Quadrivalent Influenza Virus Split Vaccine","status":"NOT_YET_RECRUITING","sponsor":"Institute of Medical Biology, Chinese Academy of Medical Sciences","startDate":"2025-02-08","conditions":"Influenza, Human, Influenza, Human Prevention, Influenza a","enrollment":4400},{"nctId":"NCT06622590","phase":"PHASE1","title":"Phase I Clinical Trial of Quadrivalent Influenza Virus Split Vaccine","status":"ACTIVE_NOT_RECRUITING","sponsor":"Institute of Medical Biology, Chinese Academy of Medical Sciences","startDate":"2024-10-13","conditions":"Influenza, Human, Influenza a, Influenza Type B","enrollment":180},{"nctId":"NCT02871206","phase":"PHASE4","title":"Adjuvanted Inactivated Vaccine Versus Inactivated Influenza Vaccine in Hutterite Children","status":"COMPLETED","sponsor":"McMaster University","startDate":"2016-11","conditions":"Influenza","enrollment":3425},{"nctId":"NCT05284799","phase":"PHASE2","title":"Immunogenicity and Safety of the Concomitant Administration of OVX836 and Quadrivalent Influenza Vaccine in Healthy Volunteers.","status":"COMPLETED","sponsor":"Osivax","startDate":"2022-05-09","conditions":"Influenza","enrollment":180},{"nctId":"NCT05568797","phase":"PHASE3","title":"A Study on the Immune Response and Safety of a Vaccine Against Respiratory Syncytial Virus (RSV) When Given Alone or Co-administered With an Adjuvanted Vaccine Against Influenza in Adults Aged 65 Years and Above","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2022-10-14","conditions":"Respiratory Syncytial Virus Infections","enrollment":1045},{"nctId":"NCT05559476","phase":"PHASE3","title":"A Study on the Immune Response and Safety Elicited by a Vaccine Against Respiratory Syncytial Virus (RSV) When Given Alone and Together With a Vaccine Against Influenza in Adults Aged 65 Years and Above","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2022-10-20","conditions":"Respiratory Syncytial Virus Infections","enrollment":1029},{"nctId":"NCT04841577","phase":"PHASE3","title":"A Study on the Immune Response and Safety Elicited by a Vaccine Against Respiratory Syncytial Virus (RSV) When Given Alone and Together With a Vaccine Against Influenza in Adults Aged 60 Years and Above","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2021-04-27","conditions":"Respiratory Syncytial Virus Infections","enrollment":976},{"nctId":"NCT05431725","phase":"PHASE3","title":"Immunogenicity and Safety Study of Influenza Vaccine (Split Virion), Inactivated, Quadrivalent","status":"COMPLETED","sponsor":"Sinovac Biotech Co., Ltd","startDate":"2022-07-18","conditions":"Seasonal Influenza","enrollment":2202},{"nctId":"NCT05245552","phase":"PHASE3","title":"A Clinical Trial of Quadrivalent Influenza Vaccine in Healthy Subjects Aged 6 to 35 Months","status":"COMPLETED","sponsor":"Sinovac Biotech Co., Ltd","startDate":"2022-08-08","conditions":"Seasonal Influenza","enrollment":217},{"nctId":"NCT03615482","phase":"PHASE3","title":"A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 When Administered Concomitantly With Influenza Vaccine in Healthy Adults 50 Years of Age or Older (V114-021/PNEU-FLU)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2018-09-14","conditions":"Pneumococcal Infections","enrollment":1200},{"nctId":"NCT05642078","phase":"PHASE3","title":"Phase Ⅲ Clinical Study of Quadrivalent Influenza Virus Split Vaccine","status":"COMPLETED","sponsor":"Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.","startDate":"2023-02-18","conditions":"Prevention of Influenza","enrollment":2550},{"nctId":"NCT04576377","phase":"PHASE4","title":"Dynamics of the Immune Responses to Repeat Influenza Vaccination Exposures","status":"UNKNOWN","sponsor":"The University of Hong Kong","startDate":"2020-10-05","conditions":"Influenza, Human","enrollment":977},{"nctId":"NCT05047770","phase":"PHASE3","title":"A Study on the Immune Response and Safety of the Shingles Vaccine and the Influenza Vaccine When Either is Given to Healthy Adults at the Same Time or Following a COVID-19 Booster Vaccine","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2021-10-07","conditions":"Herpes Zoster","enrollment":2013},{"nctId":"NCT05044195","phase":"PHASE3","title":"A Clinical Study to Evaluate the Immunogenicity and Safety of an Adjuvanted Quadrivalent Influenza Vaccine Compared With a Licensed Quadrivalent Vaccine in Adults 50 to 64 Years of Age","status":"COMPLETED","sponsor":"Seqirus","startDate":"2021-09-30","conditions":"Influenza, Human","enrollment":2044},{"nctId":"NCT02677493","phase":"PHASE3","title":"Study to Evaluate the Immunogenicity and Safety of 'IL-YANG Quadrivalent Influenza Vaccine Inj.'","status":"COMPLETED","sponsor":"Il-Yang Pharm. Co., Ltd.","startDate":"2015-10","conditions":"Influenza","enrollment":1794},{"nctId":"NCT05739474","phase":"PHASE3","title":"Tolerability, Safety and Immunogenicity Trial of the Flu-M Tetra Vaccine in Children","status":"UNKNOWN","sponsor":"St. Petersburg Research Institute of Vaccines and Sera","startDate":"2022-01-19","conditions":"Influenza, Influenza, Human, Influenza Viral Infections","enrollment":948},{"nctId":"NCT05996549","phase":"PHASE4","title":"Cost-effectiveness of the Influenza Vaccination","status":"UNKNOWN","sponsor":"International Centre for Diarrhoeal Disease Research, Bangladesh","startDate":"2022-09-29","conditions":"Influenza Vaccine, Cost-Effectiveness, Vaccination","enrollment":2567},{"nctId":"NCT03301051","phase":"PHASE3","title":"Efficacy, Safety, and Immunogenicity of a Plant-Derived Quadrivalent Virus-Like Particles (VLPs) Influenza Vaccine in Adults","status":"COMPLETED","sponsor":"Medicago","startDate":"2017-08-31","conditions":"Virus Diseases, RNA Virus Infections, Respiratory Tract Diseases","enrollment":10160},{"nctId":"NCT04622592","phase":"PHASE1, PHASE2","title":"Adjuvanted Seasonal Recombinant Quadrivalent Virus-Like Particles (QVLP) Influenza Vaccine in Adults 65 Years of Age and Older","status":"COMPLETED","sponsor":"Medicago","startDate":"2020-11-02","conditions":"Influenza","enrollment":209},{"nctId":"NCT03669627","phase":"PHASE2","title":"CT18 Infant Influenza Priming Study in Vaccine Naive Infants","status":"COMPLETED","sponsor":"Canadian Immunization Research Network","startDate":"2018-11-01","conditions":"Influenza","enrollment":159},{"nctId":"NCT01964989","phase":"PHASE3","title":"Clinical Study to Evaluate the Safety, Immunogenicity and Efficacy of Investigational Flu Vaccine Compared to Approved Flu Vaccine in Children.","status":"COMPLETED","sponsor":"Seqirus","startDate":"2013-11","conditions":"Influenza Virus","enrollment":10644},{"nctId":"NCT05212623","phase":"PHASE1","title":"A Clinical Trial of an Quadrivalent Inactivated Influenza Vaccine in Healthy Children Aged 6 to 35 Months","status":"COMPLETED","sponsor":"Jiangsu Province Centers for Disease Control and Prevention","startDate":"2021-10-26","conditions":"Influenza","enrollment":120},{"nctId":"NCT02918006","phase":"PHASE2","title":"A Phase 2 Influenza A Challenge Study Following Oral Administration of an H1N1 HA Ad-Vector Seasonal Flu Vaccine","status":"COMPLETED","sponsor":"Vaxart","startDate":"2016-08-31","conditions":"Influenza","enrollment":179},{"nctId":"NCT05480436","phase":"PHASE4","title":"Immunogenicity and Safety of BBIBP-Corv Coadministered With PPV23 and IIV4 in Hemodialysis Population","status":"UNKNOWN","sponsor":"China National Biotec Group Company Limited","startDate":"2022-08-05","conditions":"Hemolysis, COVID-19","enrollment":1200},{"nctId":"NCT05048589","phase":"PHASE2","title":"Feasibility of Randomizing Danish Citizens Aged 65-79 Years to High-Dose Quadrivalent Influenza Vaccine vs. Standard-Dose Quadrivalent Influenza Vaccine in a Pragmatic Registry-Based Setting","status":"COMPLETED","sponsor":"Tor Biering-Sørensen","startDate":"2021-10-01","conditions":"Influenza","enrollment":12551},{"nctId":"NCT05499351","phase":"PHASE4","title":"A Study of Booster Immunization With COVID-19 Vaccine,Inactivated Co -Administration With Influenza Vaccine and Pneumococcal Polysaccharide Vaccine","status":"COMPLETED","sponsor":"Sinovac Biotech Co., Ltd","startDate":"2021-10-15","conditions":"COVID-19","enrollment":3000},{"nctId":"NCT05494047","phase":"PHASE3","title":"Phase Ⅲ, Clinical Trial to Compare an Inactivated Quadrivalent Influenza Vaccine and a Licensed Vaccine in Chile","status":"UNKNOWN","sponsor":"Pontificia Universidad Catolica de Chile","startDate":"2022-07-14","conditions":"Influenza, Vaccines","enrollment":1600},{"nctId":"NCT04559204","phase":"PHASE4","title":"Evaluation of Safety and Immunogenicity of Combined Immunization of PPV23 and IIV4","status":"COMPLETED","sponsor":"China National Biotec Group Company Limited","startDate":"2020-09-11","conditions":"Influenza, Human, Pneumonia, Pneumococcal","enrollment":1224},{"nctId":"NCT04790851","phase":"PHASE4","title":"Evaluation of Immunogenicity and Safety of Combined Immunization of COVID-19 Vaccine (Produced in Beijing) and PPV23 / IIV4","status":"COMPLETED","sponsor":"China National Biotec Group Company Limited","startDate":"2021-03-10","conditions":"Influenza, Human, Pneumonia, Pneumococcal, Covid19","enrollment":1133},{"nctId":"NCT05079152","phase":"PHASE4","title":"Evaluation of Immunogenicity and Safety of Combined Immunization of COVAX (Produced in Wuhan) and PPV23 / IIV4","status":"UNKNOWN","sponsor":"China National Biotec Group Company Limited","startDate":"2021-05-06","conditions":"Influenza, Human, Pneumonia, Pneumococcal, COVID-19 Pneumonia","enrollment":1404},{"nctId":"NCT04439695","phase":"PHASE1","title":"Study to Evaluate the Safety and Immunogenicity of KBP-V001 Quadrivalent Influenza Vaccine in Healthy Adults","status":"COMPLETED","sponsor":"KBio Inc","startDate":"2020-06-25","conditions":"Influenza","enrollment":120},{"nctId":"NCT04984408","phase":"PHASE3","title":"Efficacy, Immunogenicity and Safety of BBIBP-CorV Vaccine Against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection.","status":"UNKNOWN","sponsor":"International Vaccine Institute","startDate":"2021-10-01","conditions":"COVID-19 Disease","enrollment":8825},{"nctId":"NCT04848467","phase":"PHASE3","title":"COVID-19: A Trial Studying the SARS-CoV-2 mRNA Vaccine CVnCoV to Learn About the Immune Response, the Safety, and the Degree of Typical Vaccination Reactions When CVnCoV is Given at the Same Time as a Flu Vaccine Compared to When the Vaccines Are Separately Given in Adults 60 Years of Age and Older","status":"WITHDRAWN","sponsor":"Bayer","startDate":"2021-10-01","conditions":"SARS-CoV-2 Infection, Coronavirus Disease 2019 (COVID-19)","enrollment":""},{"nctId":"NCT04143451","phase":"PHASE3","title":"Intradermal Influenza Vaccine With Topical Imiquimod in Elderly and Chronic Illness Patients","status":"UNKNOWN","sponsor":"The University of Hong Kong","startDate":"2019-10-23","conditions":"Influenza","enrollment":4000},{"nctId":"NCT03448705","phase":"PHASE1","title":"Safety of 4Fluart ID Suspension for Injection in Adult Subjects","status":"COMPLETED","sponsor":"Fluart Innovative Vaccine Ltd, Hungary","startDate":"2018-01-31","conditions":"Human Influenza","enrollment":36},{"nctId":"NCT03926416","phase":"PHASE1","title":"Safety Study of Live Attenuated Influenza Vaccine, CodaVax","status":"COMPLETED","sponsor":"Codagenix, Inc","startDate":"2017-02-21","conditions":"Influenza","enrollment":125},{"nctId":"NCT03058692","phase":"PHASE2","title":"Two Doses of Multimeric-001 (M-001) Followed by Influenza Vaccine","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2018-04-09","conditions":"Influenza, Influenza Immunisation","enrollment":120},{"nctId":"NCT02587221","phase":"PHASE3","title":"Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Influenza Vaccine Compared to Non-influenza Vaccine Comparator in Adults ≥ 65 Years of Age","status":"COMPLETED","sponsor":"Seqirus","startDate":"2016-09-30","conditions":"Influenza","enrollment":6790},{"nctId":"NCT03460743","phase":"PHASE3","title":"Evaluation of a Recombinant Quadrivalent Influenza Vaccine Versus a Marketed Quadrivalent Inactivated Influenza Vaccine in Children 3 to 17.","status":"COMPLETED","sponsor":"Laboratorios Liomont","startDate":"2018-03-22","conditions":"Influenza, Human","enrollment":1556},{"nctId":"NCT03718468","phase":"PHASE3","title":"A Study to Evaluate the Safety and Immunogenicity of Quadrivalent Influenza Vaccine","status":"COMPLETED","sponsor":"Medigen Vaccine Biologics Corp.","startDate":"2018-10-30","conditions":"Influenza","enrollment":842},{"nctId":"NCT03859141","phase":"PHASE3","title":"Clinical Trial to Evaluate the Safety and Immunogenicity of Quadrivalent Influenza Vaccine (7.5μg/0.25ml)","status":"COMPLETED","sponsor":"Sinovac Biotech Co., Ltd","startDate":"2018-02-06","conditions":"Seasonal Influenza","enrollment":2340},{"nctId":"NCT03853993","phase":"PHASE3","title":"Clinical Trial to Evaluate the Safety and Immunogenicity of Quadrivalent Influenza Vaccine (15µg/0.5ml)","status":"COMPLETED","sponsor":"Sinovac Biotech Co., Ltd","startDate":"2018-01-23","conditions":"Seasonal Influenza","enrollment":2380},{"nctId":"NCT03657719","phase":"PHASE2","title":"A Study to Evaluate the Safety and Efficacy(Immunogenicity) of GC3114 in Elderly Healthy Subjects","status":"COMPLETED","sponsor":"Green Cross Corporation","startDate":"2018-10-01","conditions":"Influenza, Human","enrollment":105},{"nctId":"NCT03437304","phase":"PHASE1, PHASE2","title":"Study to Assess the Safety, Tolerability and Immune Response Following Vaccination With Immunose™ FLU in Older Adults","status":"COMPLETED","sponsor":"Eurocine Vaccines AB","startDate":"2018-02-09","conditions":"Influenza","enrollment":298},{"nctId":"NCT03357263","phase":"PHASE1","title":"A Study to Evaluate the Safety and Efficacy(Immunogenicity) of GC3114 in Healthy Adults","status":"COMPLETED","sponsor":"Green Cross Corporation","startDate":"2017-11-20","conditions":"Influenza, Human","enrollment":40},{"nctId":"NCT01439360","phase":"PHASE3","title":"An Efficacy Study of GlaxoSmithKline (GSK) Biologicals' Candidate Influenza Vaccine GSK2321138A in Children","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2011-10-01","conditions":"Influenza","enrollment":12046},{"nctId":"NCT00952705","phase":"PHASE3","title":"A Study to Evaluate the Immunogenicity of Quadrivalent LAIV (MEDI8662) in Adults 18 to 49 Years of Age","status":"COMPLETED","sponsor":"MedImmune LLC","startDate":"2009-08","conditions":"Healthy or Stable Underlying Chronic Medical Condition","enrollment":1800},{"nctId":"NCT01954251","phase":"PHASE3","title":"Study to Evaluate the Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Vaccine GSK1437173A When Co-administered With GSK Biologicals' Seasonal Influenza Vaccine GSK2321138A in Adults Aged 50 Years and Older","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2013-10-03","conditions":"Herpes Zoster","enrollment":829},{"nctId":"NCT03502291","phase":"PHASE4","title":"The Effect of Live Attenuated Inactivated Influenza Vaccine on Experimental Human Pneumococcal Carriage Study","status":"COMPLETED","sponsor":"Liverpool University Hospitals NHS Foundation Trust","startDate":"2015-08","conditions":"Pneumonia, Influenza, Human","enrollment":324},{"nctId":"NCT02218697","phase":"PHASE3","title":"Evaluation of the Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Quadrivalent Influenza Vaccine Influsplit™ Tetra (Fluarix™ Tetra) (GSK2321138A) When Co-administered With Pneumovax™ 23 in Adults 50 Years of Age and Older","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2014-10-01","conditions":"Influenza","enrollment":357},{"nctId":"NCT02541253","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of 'GC3110A(QIV)' in Healthy Children","status":"COMPLETED","sponsor":"Green Cross Corporation","startDate":"2015-09","conditions":"Influenza","enrollment":543},{"nctId":"NCT02290509","phase":"PHASE3","title":"Safety and Immunogenicity of Flublok Quadrivalent vs IIV4 in Adults 18-49 Years of Age","status":"COMPLETED","sponsor":"Protein Sciences Corporation","startDate":"2014-10","conditions":"Influenza","enrollment":1350},{"nctId":"NCT02710409","phase":"PHASE3","title":"A Phase III Clinical Trial of An Inactivated Quadrivalent Influenza Vaccine in Healthy Subjects Aged 3 Years and Older","status":"COMPLETED","sponsor":"Jiangsu Province Centers for Disease Control and Prevention","startDate":"2016-01","conditions":"Influenza","enrollment":3664},{"nctId":"NCT02658409","phase":"PHASE3","title":"A Multicenter, Double-blind, Parallel, Non-inferiority, Phase III Study","status":"UNKNOWN","sponsor":"Green Cross Corporation","startDate":"2015-11","conditions":"Influenza","enrollment":1630},{"nctId":"NCT02352584","phase":"PHASE3","title":"A Multicenter, Double-blind, Parallel Phase III Study","status":"COMPLETED","sponsor":"Green Cross Corporation","startDate":"2014-10","conditions":"Influenza","enrollment":1299},{"nctId":"NCT02434276","phase":"PHASE2","title":"Study of the Immunogenicity and Safety of a Quadrivalent Influenza Vaccine (VAX2012Q) in Adults 18-64 Years","status":"UNKNOWN","sponsor":"VaxInnate Corporation","startDate":"2015-05","conditions":"Influenza","enrollment":450},{"nctId":"NCT02247362","phase":"PHASE1, PHASE2","title":"Study of Safety and Immunogenicity of a Quadrivalent Influenza Vaccine in Healthy Adults Age 65-75 Years","status":"UNKNOWN","sponsor":"VaxInnate Corporation","startDate":"2014-11","conditions":"Influenza","enrollment":200},{"nctId":"NCT02121782","phase":"PHASE1, PHASE2","title":"A Phase I/IIa Study of GC3110A (Quadrivalent Influenza Vaccine)","status":"COMPLETED","sponsor":"Green Cross Corporation","startDate":"2014-05","conditions":"Influenza","enrollment":84},{"nctId":"NCT01810731","phase":"PHASE2, PHASE3","title":"Safety and Immunogenicity Study of Influenza Vaccines in HIV-infected and HIV-uninfected Pregnant Women in Western Kenya","status":"WITHDRAWN","sponsor":"Centers for Disease Control and Prevention","startDate":"2014-04","conditions":"Influenza, Human, HIV, Malaria","enrollment":""},{"nctId":"NCT00860067","phase":"PHASE2, PHASE3","title":"A Study to Evaluate the Immunogenicity of Quadrivalent LAIV in Adults 18 to 49 Years of Age","status":"COMPLETED","sponsor":"MedImmune LLC","startDate":"2009-03","conditions":"Healthy or Stable Underlying Chronic Medical Condition","enrollment":1800}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":40,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"QIV control","genericName":"QIV control","companyName":"Institute of Medical Biology, Chinese Academy of Medical Sciences","companyId":"institute-of-medical-biology-chinese-academy-of-medical-sciences","modality":"Biologic","firstApprovalDate":"","aiSummary":"QIV control is a vaccine that stimulates the body's immune system to produce antibodies against the influenza virus. Used for Prevention of influenza disease caused by four different strains of the influenza virus.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":2,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}